Open AccessRisk of de novo Hepatocellular Carcinoma after HCV Treatment with Direct-Acting Antivirals
Author(s) -
Fabian Finkelmeier,
G. Dultz,
KaiHenrik Peiffer,
Bernd Kronenberger,
Franziska Krauss,
Stefan Zeuzem,
Christoph Sarrazin,
Johannes Vermehren,
Oliver Waidmann
Publication year - 2018
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 2235-1795
pISSN - 1664-5553
DOI - 10.1159/000486812
Subject(s) - medicine , hepatocellular carcinoma , gastroenterology , cohort , cirrhosis , hepatitis c virus , hepatitis b , immunology , virus
The aim of the study was to evaluate the risk of hepatocellular carcinoma (HCC) development after treatment with direct-acting antivirals (DAAs) and to compare HCC occurrence in these patients with that among patients treated with interferon (IFN)-based therapies.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom